Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Payables: 2022-2024

Historic Payables for Immunocore Holdings (IMCR) over the last 3 years, with Dec 2024 value amounting to $25.1 million.

  • Immunocore Holdings' Payables fell 66.21% to $23.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.0 million, marking a year-over-year decrease of 16.63%. This contributed to the annual value of $25.1 million for FY2024, which is 41.03% up from last year.
  • Immunocore Holdings' Payables amounted to $25.1 million in FY2024, which was up 41.03% from $17.8 million recorded in FY2023.
  • Over the past 5 years, Immunocore Holdings' Payables peaked at $25.1 million during FY2024, and registered a low of $14.4 million during FY2022.
  • Its 3-year average for Payables is $19.1 million, with a median of $17.8 million in 2023.
  • Data for Immunocore Holdings' Payables shows a peak YoY spiked of 41.03% (in 2024) over the last 5 years.
  • Over the past 3 years, Immunocore Holdings' Payables (Yearly) stood at $14.4 million in 2022, then grew by 23.17% to $17.8 million in 2023, then spiked by 41.03% to $25.1 million in 2024.